Retatrutide has become the poster child for how fast a compound can move from clinical trial to grey market. It’s not even approved yet, and it’s already being sold by third-party vendors, compounding pharmacies and telehealth outfits at a scale big enough that Eli Lilly filed six lawsuits in August to shut down the knock-off trade. We’ve tracked this grey market and the lawsuits as they’ve developed.
Two things happened this week that sharpen the picture considerably, and both matter to anyone in the Australian research-community space. First, real-world data showing that people buying “reta” outside clinical trials lose a lot less weight than trial participants. Second, a cluster of liver-toxicity cases in Victoria linked to counterfeit/unapproved peptides.
The weight-loss gap data
A study from a Massachusetts-based data analytics company, picked up by the Partnership for Safe Medicines, compared weight loss in people using retatrutide outside clinical trials against the documented trial results. The gap is stark.
Black-market users lost an average of 4.7% of their body weight after three months, 5.3% after six months, and 7.2% after a year. Clinical trial participants lost 5.7%, 11.9% and 15.5% over the same intervals. In other words, at the one-year mark the grey-market users saw less than half the weight loss of the people in the actual trials - 7.2% versus 15.5%.
That’s a massive divergence, and it’s the kind of number the community needs to sit with. It’s not just “the drug might be weaker.” It suggests that what people are actually getting off the grey market is frequently not the same as what was studied.
Why the grey market loses so much efficacy
The report flags the obvious structural reasons. People who leave the secure supply chain risk getting drugs that aren’t the strength they claim to be, or that contain entirely different active ingredients. Third-party vendors often import from facilities that may not be adequate for sterile production, and some have faked their certificates of analysis.
The sourcing data is telling: of the 378 subjects in the study taking black-market drugs, 57% got the drug from online or telehealth vendors, 29% from compounding pharmacies, and 9% from wellness clinics. Only a small remainder came from anything resembling a verified channel.
This tracks exactly with what we’ve seen reported across the grey market this year - a supply chain where the product may be real, diluted, mislabelled, or something else entirely, and where the buyer has no way to tell the difference from the vial in front of them. The 30%-plus weight-loss figures that made retatrutide famous come from the Phase 3 trial data. Expecting those numbers from an unidentified third-party vial is a gamble, and the data now says the average outcome is far closer to half that.
Victoria’s liver-toxicity cluster
The other development is Australian and it’s serious. Victorian health authorities have been investigating cases of liver toxicity, with reports that seven people have been hospitalised in Victoria after using counterfeit retatrutide. ABC News reported over the weekend that “contaminated” unapproved peptides may be behind the liver-failure cases.
This follows earlier reporting through June about a Melbourne woman who suffered acute liver failure after using a knock-off drug, and six hospitalisations flagged around the same time. The seventh case in the current reporting cycle has raised concerns about a particular peptide batch circulating in the state.
There’s an image circulating from the Partnership for Safe Medicines tagging the Victorian retatrutide liver-failure situation specifically, and they’ve been amplifying the case because it’s exactly the failure mode they warn about: unapproved, understudied, improperly sourced injectable peptides causing real harm.
Let me be direct about this, because it’s the kind of thing where the community deserves clear framing rather than hedging. The Australian picture is not a simple “black market bad, trials good” story - the whole grey market exists for a reason, including drug shortages and cost. But a cluster of hospitalisations from liver failure, on top of data showing the grey-market product underperforms trials dramatically, is a signal that the people buying unapproved injectable retatrutide or similar peptides from unverified sources in Australia are taking on real, documented risk with less upside than the marketing suggests.
What the Research Says
Evidence this week, in brief:
- Black-market retatrutide users lost on average 7.2% of body weight at 12 months versus 15.5% in clinical trials - less than half the effect.
- At 3 and 6 months the gap was similar: 4.7% vs 5.7%, and 5.3% vs 11.9%.
- Of 378 grey-market users, 57% sourced from online/telehealth vendors, 29% from compounding pharmacies, 9% from wellness clinics.
- Reports of seven hospitalisations in Victoria linked to counterfeit retatrutide/unapproved peptides, with contaminated batches suspected behind liver-failure cases.
- Victorian authorities have been investigating these cases since June, following earlier acute-liver-failure reporting.
Caveats worth keeping honest:
- The weight-loss comparison is not a head-to-head trial; it’s observational real-world data against trials, so it can’t fully disentangle differences in dose, adherence or user characteristics.
- The “black market” label covers a wide and heterogeneous supply chain - some of it is real drug, some diluted, some mislabelled.
- The Victoria cluster reports are being investigated; final attribution to a specific product or batch is not yet settled.
- Retatrutide itself remains unapproved and understudied for obesity outside trials - the grey market is using a drug that hasn’t even finished its regulatory journey.
The Australian angle
For the Australian community specifically, this is the intersection of everything the TGA has been warning about. The TGA has spent 2026 cracking down on unapproved peptide supply, and we’ve covered that enforcement push here and the regulatory reality here. The Victoria cluster is the concrete harm case that enforcement warnings have been pointing at - it’s no longer hypothetical.
It’s also worth underlining that this is about supply-chain integrity, not about the compound’s legitimate research potential. Retatrutide remains one of the most promising triple-agonist candidates in the pipeline. The problem is never the compound in a well-run trial - it’s the unverified version sold as “reta” with fake certificates of analysis and unknown provenance. The data this week says those two things are not the same product, and the difference shows up in both the scale and the harm.
As always, Grey Highway is a research-education community. We don’t sell or supply compounds, and we’re not telling anyone what to do. But when the data shows grey-market users getting half the effect while face-to-face reporting flags hospitalisations in our own state, that’s information worth sharing plainly so people can weigh it honestly.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.
Sources: Partnership for Safe Medicines, “Study finds black market retatrutide is not as effective as the clinical trial versions”, 24 Aug 2026 (safemedicines.org). ABC News, “‘Contaminated’ unapproved peptides may be behind liver failure cases”, 24 Aug 2026. Partnership for Safe Medicines, “The retatrutide black market: Patient safety groups warn of growing risks from understudied drugs”, 19 Aug 2026. BioPharma Dive, “Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide”, 12 Aug 2026.